In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

This study is testing an innovative approach to CAR-T cell therapy — a type of treatment that reprograms immune cells to attack cancer — delivered directly inside the body (in vivo), rather than removing and modifying cells in a lab first. The trial targets relapsed or treatment-resistant blood cancers including certain leukemias, lymphomas, and multiple myeloma. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL), B-cell lymphoma, or multiple myeloma - You are in reasonably good physical condition (ECOG score 0–2) with an expected survival of at least 3 months - Your blood counts and organ function meet minimum thresholds **You may NOT be eligible if...** - Your cancer has not relapsed or is still responding to current treatment - You have very poor organ function or very low blood counts - You have had recent serious infections or uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.